| Literature DB >> 25439022 |
Jennifer Harrington1, Etienne Sochett1, Andrew Howard2.
Abstract
Osteogenesis imperfecta (OI) is a heritable bone fragility disorder that presents with a wide clinical phenotype spectrum: from perinatal lethality and severe deformities to very mild forms without fractures. Most cases of OI are due to autosomal dominant mutations of the type I collagen genes. A multidisciplinary approach with rehabilitation, orthopedic surgery, and consideration of medical therapy with bisphosphonates underpins current management. Greater understanding of the pathogenesis of OI may lead to novel, therapeutic approaches to help improve clinical symptoms of children with OI in the future.Entities:
Keywords: Bisphosphonates; Collagen; Fractures; Osteogenesis imperfecta
Mesh:
Substances:
Year: 2014 PMID: 25439022 DOI: 10.1016/j.pcl.2014.08.010
Source DB: PubMed Journal: Pediatr Clin North Am ISSN: 0031-3955 Impact factor: 3.278